GlassScriptPhysician profile
Kaitlin Walls
NPI 1457884231
$2,480.49
in general payments reported to CMS, 2019-2025
22 companies · $767 in 2025
The $767 reported for 2025 was more than what 81% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $412 · 2022: $597 · 2023: $292 · 2024: $413 · 2025: $767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,372 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,372.08 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $542.82 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $378.16 | 2021-2025 | Xifaxan |
| Janssen Biotech, INC. | $209.95 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Redhill Biopharma INC. | $200.54 | 2021-2025 | Talicia, Aemcolo |
| Madrigal Pharmaceuticals | $193.39 | 2024-2025 | Rezdiffra, Resmetirom |
| Braintree Laboratories, INC. | $155.76 | 2022-2025 | Sutab, Suflave |
| Takeda Pharmaceuticals U.S.A., INC. | $124.21 | 2021-2025 | Entyvio, Gattex |
| Phathom Pharmaceuticals, INC. | $122.84 | 2024-2025 | Voquezna |
| Celgene Corporation | $81.21 | 2022-2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $73.35 | 2021 | |
| Ironwood Pharmaceuticals, INC | $53.69 | 2024 | |
| Pfizer INC. | $51.33 | 2025 | |
| Gilead Sciences, INC. | $49.89 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $47.46 | 2024-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $44.35 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $35.85 | 2022-2025 | |
| Csl Behring | $31.93 | 2021 | |
| Ardelyx, INC. | $24.32 | 2022 | |
| Glaxosmithkline, LLC. | $16.13 | 2021 | |
| Genzyme Corporation | $15.38 | 2021 | |
| Vivus LLC | $15.10 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaitlin Walls listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.